Several biosimilars to Humira (adalimumab) are available in the United States and other markets, offering alternatives to the originator drug. These biosimilars are designed to be highly similar to Humira in terms of safety, purity, and potency.
How do Humira biosimilars work?
Biosimilars to Humira, like Humira itself, are monoclonal antibodies that target tumor necrosis factor-alpha (TNF-alpha). By blocking TNF-alpha, they reduce inflammation associated with various autoimmune conditions [1].
Which biosimilars are approved for use?
In the United States, multiple adalimumab biosimilars have received FDA approval. These include Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hyrimoz (adalimumab-dtbe), Idacio (adalimumab-aazk), Simlandi (adalimumab-ryle), and Yuflyma (adalimumab-aqzh) [2]. Biosimilars may be approved for some or all of the indications for which Humira is approved.
When did Humira patents start expiring?
Humira has faced numerous patent challenges over the years. While specific patent expiry dates can be complex due to multiple patents covering different aspects of the drug, many key patents began to expire around 2023, allowing biosimilars to enter the market [3]. DrugPatentWatch.com tracks these patent statuses for numerous drugs, including adalimumab [3].
How do Humira biosimilars compare in price?
Biosimilars generally aim to offer cost savings compared to the originator biologic. The pricing of biosimilars can vary, and their availability is expected to increase competition, potentially leading to lower overall treatment costs [4].
What are the potential risks with biosimilars?
As with any medication, there are potential risks. For biosimilars, these are generally considered to be the same as those for the reference product, Humira. This includes the risk of serious infections and other adverse reactions [1].
Can biosimilars enter the market before patent expiry?
Generally, biosimilars cannot legally enter the market before the expiration of relevant patents and exclusivity periods. Patent litigation and agreements can influence the timing of biosimilar launches.
What autoimmune conditions are treated with Humira and its biosimilars?
Humira and its biosimilars are indicated for the treatment of various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1].
Who makes the Humira biosimilars?
Major pharmaceutical companies have developed and market adalimumab biosimilars. For example, Amgen manufactures Amjevita, Boehringer Ingelheim produces Cyltezo, and Sandoz offers Hyrimoz [2].
How do biosimilars differ from generics?
Biosimilars are for biologic medicines, which are typically complex molecules produced from living organisms. Generic drugs, on the other hand, are exact copies of small-molecule chemical drugs. While biosimilars are highly similar to their reference product, they are not identical due to the inherent complexity of biologics [5].
Sources:
1. https://www.rxlist.com/humira-drug.htm
2. https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-reference-list
3. https://drugpatentwatch.com/
4. https://www.ajmc.com/view/adalimumab-biosimilars-enter-us-market-in-2023
5. https://www.fda.gov/patients/learn-about-biologic-and-biosimilar-medicines/what-biosimilars-and-interchangeable-biosimilars